Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn’s disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study

Autor: Christien Janneke van der Woude, Emma Paulides, Mitchell R K L Lie

Publikováno v: BMJ Open, Vol 12, Iss 4 (2022)

Introduction Crohn’s disease (CD) is an inflammatory bowel disease (IBD). Several drugs exist to induce and maintain remission, but a significant part of the patients is refractory to current IBD drugs or experiences side effects. Whether low-dose

Externí odkaz: https://doaj.org/article/0fea93e18d4d4cc0b553d22e3b6768e1

Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn's disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study

Autor: Emma Paulides, Mitchell R K L Lie, Christien Janneke van der Woude

Publikováno v: BMJ Open, 12(4):e058358. BMJ Publishing Group

IntroductionCrohn’s disease (CD) is an inflammatory bowel disease (IBD). Several drugs exist to induce and maintain remission, but a significant part of the patients is refractory to current IBD drugs or experiences side effects. Whether low-dose n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ac234ebd81327b1a38743bb47c252d1
https://pubmed.ncbi.nlm.nih.gov/35396307

No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis

Autor: Andrea E. van der Meulen de Jong, Christien J. van der Woude, Mitchell R. K. L. Lie, Rachel L. West, Mark Löwenberg, Désirée van Noord, Rianne J. Zaal, Gert Van Assche, Bas Oldenburg, Gerard Dijkstra, Bettina E. Hansen, Joany E. Kreijne, Annemarie C. de Vries

Publikováno v: Clinical Gastroenterology and Hepatology, 18(8), 1777-1784.e2. ELSEVIER SCIENCE INC
Clinical gastroenterology and hepatology, 18(8), 1777-1784.e2. W.B. Saunders Ltd

BACKGROUND & AIMS: Ulcerative proctitis (UP) refractory to 5-aminosalicylic acid (5-ASA) suppositories is a challenge to treat, often requiring step up to immunomodulator or biological therapy. Topical tacrolimus is effective and safe in patients wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afdc476e12402e3c025ac75ae21aac06
https://doi.org/10.1016/j.cgh.2019.09.049

P287 Patient sex does not affect endoscopic outcomes of biologicals in patients with inflammatory bowel disease, but is possibly associated with adverse events: A systematic review

Autor: Emma Paulides, C.J. van der Woude, Mitchell R. K. L. Lie

Publikováno v: Journal of Crohn's and Colitis. 14:S296-S296

Background There are several known factors influencing the efficacy and tolerability of biological therapies. Whether patient sex affects this is currently unclear, yet this knowledge would be helpful for risk and benefit stratification. This study a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5fde7918224a833ceb770c69bd82cd6b
https://doi.org/10.1093/ecco-jcc/jjz203.416

Drug Therapies for Ulcerative Proctitis: Systematic Review and Meta-analysis

Autor: Bettina E. Hansen, C. Janneke van der Woude, Shannon L. Kanis, Mitchell R. K. L. Lie

Publikováno v: Inflammatory Bowel Diseases, 20(11), 2157-2178. Oxford University Press

__Background:__ Patients with ulcerative colitis limited to the proctum are considered to have ulcerative proctitis (UP). In patients with more extensive ulcerative colitis, treatment occurs in a step-up fashion (5-ASA, corticosteroids, thiopurines,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab6ccb6746ea09af91595b178639c198
https://pure.eur.nl/en/publications/d64a1dc1-747f-48fe-bdba-5741c5b4e1e0